Key result
Brachial artery flow-mediated dilation was significantly lower in AMI patients compared to controls (10.2% vs 15.4%; p<0.001) and was inversely correlated to platelet reactivity in both groups.
Why the study?
Does brachial artery endothelial function predict platelet function in individuals without established cardiovascular disease and in patients with acute myocardial infarction?
Observational (n=151)
Does brachial artery endothelial function predict platelet function in individuals without established cardiovascular disease and in patients with acute myocardial infarction?
Absolute Event Rate: 10.2% vs 15.4%
p-value: p=<0.001
Brachial artery flow-mediated dilation is inversely correlated with platelet reactivity in both healthy controls and patients with acute myocardial infarction, suggesting a link between endothelial dysfunction and platelet activation.
Endothelial dysfunction may associate with platelet reactivity in AMI and controls; leaves open whether FMD assessment informs therapy or risk stratification.
Platelet activation occurs in an endothelium-dependent flow-mediated dilation (FMD) impairment environment. The aim of this study was to explore the association between platelet reactivity and brachial artery FMD in individuals without established cardiovascular disease (controls) and acute myocardial infarction (AMI) patients. We prospectively assessed brachial artery FMD in 151 consecutive subjects, 104 (69%) controls, and 47 (31%) AMI patients; 115 (76%) men, mean age 53 ± 11 years. Following overnight fasting and discontinuation of all medications for ≥ 12 h, percent change in brachial artery FMD (%FMD) and endothelium-independent, nitroglycerin-mediated vasodilation (%NTG) were assessed. Platelet aggregation was assessed by conventional aggregometry, and platelet adhesion and aggregation under flow conditions by cone-and-plate(let) technology (Impact-R). Smoking, diabetes, and hypertension were more common in AMI compared to control subjects (p < 0.01 for all). Furthermore, aspirin, clopidogrel, beta-blockers, angiotensin-converting enzyme inhibitors, and statin administration were more common in AMI compared to controls (p < 0.01 for all). %FMD but not %NTG was significantly lower in AMI patients compared to controls (10.2 ± 4.2% vs. 15.4 ± 4.4%; p < 0.001 and 17.2 ± 3.9% vs. 18.0 ± 3.7%, p = 0.803, respectively). %FMD was significantly and inversely associated with all platelet functions tests (p < 0.001) in all study participants. In a multivariate logistic regression (unadjusted and adjusted for age, gender, smoking status, diabetes mellitus, hypertension, hypercholesterolemia, overweight, family history, and concomitant medications), %FMD remained the best predictor of platelet function, irrespective of group allocation (AMI patients or controls). In conclusion, FMD is inversely correlated to platelet reactivity in both controls and AMI patients.
No takes yet. Share an insight, caveat, or question.
Shechter et al. (2011) conducted an observational in Acute myocardial infarction (n=151). Acute myocardial infarction vs. Controls (individuals without established cardiovascular disease) was evaluated on Percent change in brachial artery flow-mediated dilation (%FMD) (p=<0.001). Brachial artery flow-mediated dilation was significantly lower in AMI patients compared to controls (10.2% vs 15.4%; p<0.001) and was inversely correlated to platelet reactivity in both groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: